Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to save memories: new study tests magnetic stimulation for mild cognitive impairment

NCT ID NCT03962959

Symptom relief Sponsor: University of Arizona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a painless, non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) could improve memory in people with mild cognitive impairment (MCI), a condition that often leads to Alzheimer's disease. Researchers used MRI scans to personalize the stimulation location and pattern for each of the 97 participants. The goal was to find the best way to boost brain activity in the hippocampus, a key memory center, and potentially slow cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS) using theta burst stimulation
What this could lead to
If successful, this approach could offer a non-drug way to slow memory decline in people at risk for Alzheimer's disease.
What could go wrong
This was a small, early-stage study focused on feasibility and personalizing stimulation. It may not lead to a proven treatment, and benefits may vary between individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

97 people

The number who actually took part.

Started

Oct 2020

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Individuals with mild cognitive impairment (MCI Group) Inclusion Criteria: * Age 50-85 years * MCI clinical criteria: (a) typical comprehensive criteria (at least one cognitive test \<= -1.5 SD), or (b) Jak/Bondi criteria (2 tests within the same domain \<= -1SD or 3 tests total \<= -1SD) * Right handed * English speaking * Able to attend daily intervention (Monday-Friday) for 4 weeks * Not enrolled in another interventional study within 6 months prior to beginning this study Exclusion Criteria: * Contraindications to transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI) * Other neurological disorders (e.g. stroke, head injuries, or multiple sclerosis) * Current cancer treatment or other medical problems that might independently affect cognitive function Cognitively Normal Individuals: Inclusion Criteria: * Age 50-85 years * Right handed * English speaking * Able to attend daily intervention (Monday-Friday) for 4 weeks * Not enrolled in another interventional study within 6 months prior to beginning this study Exclusion Criteria: * Contraindications to transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI) * Other neurological disorders (e.g. stroke, head injuries, or multiple sclerosis) * Current cancer treatment or other medical problems that might independently affect cognitive function * No dementia or impaired cognitive functioning, assessed using the NACC battery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Alzheimer disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment

Contacts and locations

Locations

  • Bioscience Research Laboratory

    Tucson, Arizona, 85719, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.